Source: Okayama University (JAPAN), Public Relations and Information Strategy
For immediate release: 26 January 2017
Okayama University research: Attacking tumors from the inside

(Okayama, 26 January) A specially-created group of immune cells that can infiltrate cancer cells can successfully deliver viral vectors into tumors and destroy them from the inside.

The targeted delivery of drugs directly into cancer cells is becoming an increasingly common method of ensuring more accurate, safer cancer treatments. Scientists are now exploring the concept of using specially-created groups of immune cells to carry biologics – drugs derived from natural sources such as viruses - to target and kill cancerous tumors.

‘Cell-in-cell’ phenomena, wherein one cell infiltrates and occupies another cell, naturally occur in the human body. For example, the process whereby foreign, harmful substances are consumed by phagocytes, or when tumor cells invade immune cells, killing them in order to flourish themselves.

Now, Toshiyoshi Fujiwara and co-workers at Okayama University and scientists across Japan have utilized cell-in-cell behavior to their advantage, developing a tumor-targeting system using a novel human T-cell line called HOZOT that naturally targets and infiltrates human cancer cells. Their results could inspire many applications in the fight against different cancers.

HOZOT cell lines are established by co-cultivating human umbilical cord blood cells with mouse stromal cells. Crucially, the HOZOT cells are toxic only to cancer cells, and do not target normal healthy tissues. The HOZOT cells infiltrate tumor cells whole, and attack them from the inside. Fujiwara’s team hypothesized that these cells could be used as carriers for biologics. In this case, the researchers developed an adenovirus (OBP-401/F35) that would spread rapidly inside the tumor, killing it from the inside.

The virus-loaded HOZOT cells behaved in the same way as virus-free HOZOT lines, and so the team proceeded with trials against various human cancer cells, including colon cancer. The HOZOT carriers significantly reduced the viability of human cancer cells and suppressed the formation of tumor spheres. Additional trials on tumor-bearing mice showed increased survival rates in those treated by the HOZOT method. Also, the HOZOT carriers appear to prevent attack on the carried virus by the host’s immune system, which would recognize the virus if it was sent into the body without HOZOT cell protection.

As Fujiwara’s team state in their paper in Scientific Reports (2016); “The unique cell-in-cell property of virus-loaded HOZOT cells provides a platform for selective delivery of biologics into human cancer cells, an outcome that has important implications for the treatment of human cancers.”

Background
Cell-based cancer treatments
The idea of enhancing the body’s own immune system defences against cancers is providing scientists with the inspiration to investigate novel, targeted drug delivery methods using immune cells. The discovery that the novel HOZOT T-cell line, derived from human umbilical cord blood, is capable of specifically targeting cancer cells by infiltrating and ending up fully inside them, motivated Fujiwara’s team to trial the HOZOT line as a biologic drug carrier.

Various strategies have been trialled for using cells to transfer drugs into cancerous tumors. Stem cell technologies provide one such method, but the stem cells lack the unique ‘cell-in-cell’ activity of the novel HOZOT cells described here. Instead, stem cell-based techniques deliver drugs to the surrounding stromal tissue in tumors, rather than right inside the cancer cells, rendering the treatment less effective.

Because many cancer treatments have already been developed using adenoviruses – viral-based drugs that attack and kill harmful tissues – many cancer patients have built up a degree of immunity to viral vectors. This is another reason why using HOZOT cells as carriers has proven successful, because the virus is protected by the cell inside the body, and the host’s immune response of releasing neutralising antibodies to target the virus is not triggered.

Future work
Fujiwara’s team believe their strategy may prove useful in combination with immunotherapy in cancer patients. The researchers will continue exploring the potential for immune cells to aid in drug delivery for the treatment of human cancers.

Reference
Teppei Onishi, Hiroshi Tazawa, Yuuri Hashimoto, Makoto Takeuchi, Takeshi Otani, Shuji Nakamura, Fuminori Sakurai, Hiroyuki Mizuguchi, Hiroyuki Kishimoto, Yuzo Umeda, Yasuhiro Shirakawa, Yasuo Urata, Shunsuke Kagawa, and Toshiyoshi Fujiwara. Tumor-specific delivery of biologics by a novel T-cell line HOZOT. Scientific Reports, 6:38060, 2016.
DOI：10.1038/srep38060
http://www.nature.com/articles/srep38060


Reference (OU-MRU) : Professor Fujiwara’s team
Vol.1：Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testingVol.7：Anticancer virus solution provides an alternative to surgeryVol.21：Combined gene transduction and light therapy targets gastric cancerVol.23：Development of low cost oral inactivated vaccines for dysentery



Correspondence to
Professor Toshiyoshi Fujiwara, M.D., Ph.D.
Department of Gastroenterological Surgery, Okayama
University Graduate School of Medicine, Dentistry and
Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku,
Okayama 700-8558, Japan
e-mail : toshi_f (a) md.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.
http://www.ges-okayama-u.com/english.html



Further information
Okayama University
1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
Public Relations and Information Strategy
E-mail: www-adm (a) adm.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.

Website: //www.okayama-u.ac.jp/index_e.html
Okayama Univ. e-Bulletin: //www.okayama-u.ac.jp/user/kouhou/ebulletin/
Okayama Univ. e-Bulletin (PDF Issues): //www.okayama-u.ac.jp/user/kouhou/ebulletin/
About Okayama University (You Tube): https://www.youtube.com/watch?v=iDL1coqPRYI
Okayama University Image Movie (You Tube): https://www.youtube.com/watch?v=_WnbJVk2elA
https://www.youtube.com/watch?v=KU3hOIXS5kk

Okayama University Medical Research Updates （OU-MRU）
Vol.1：Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testingVol.2：Ensuring a cool recovery from cardiac arrestVol.3：Organ regeneration research leaps forwardVol.4：Cardiac mechanosensitive integratorVol.5：Cell injections get to the heart of congenital defectsVol.6：Fourth key molecule identified in bone developmentVol.7：Anticancer virus solution provides an alternative to surgeryVol.8：Light-responsive dye stimulates sight in genetically blind patientsVol.9：Diabetes drug helps towards immunity against cancerVol.10：Enzyme-inhibitors treat drug-resistant epilepsyVol.11：Compound-protein combination shows promise for arthritis treatmentVol.12：Molecular features of the circadian clock system in fruit fliesVol.13：Peptide directs artificial tissue growthVol.14：Simplified boron compound may treat brain tumoursVol.15：Metamaterial absorbers for infrared inspection technologiesVol.16：Epigenetics research traces how crickets restore lost limbsVol.17：Cell research shows pathway for suppressing hepatitis B virusVol.18：Therapeutic protein targets liver diseaseVol.19：Study links signalling protein to osteoarthritisVol.20：Lack of enzyme promotes fatty liver disease in thin patientsVol.21：Combined gene transduction and light therapy targets gastric cancerVol.22：Medical supportive device for hemodialysis catheter punctureVol.23：Development of low cost oral inactivated vaccines for dysenteryVol.24：Sticky molecules to tackle obesity and diabetesVol.25：Self-administered aroma foot massage may reduce symptoms of anxietyVol.26：Protein for preventing heart failureVol.27：Keeping cells in shape to fight sepsisVol.28：Viral-based therapy for bone cancerVol.29：Photoreactive compound allows protein synthesis control with lightVol.30：Cancer stem cells’ role in tumor growth revealedVol.31：Prevention of RNA virus replicationVol.32：Enzyme target for slowing bladder cancer invasion